Nanobac Pharmaceuticals, Incorporated
NNBP
Other OTC0.00
USD
- -
- -
ISIN
US63007M1027
CUSIP
63007M102
Return %
Stock
S&P500
1Y
0.00
19.01
3Y
- -
65.48
5Y
-50.00
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- John Stanton
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3000 Bayport Drive Tampa FL United States of America 33607
- IPO Date
- Oct 31, 1994
- Website
- nanobac.com
- Similar Companies
- Business
- Nanobac Pharmaceuticals, Incorporated is a bio-lifescience company primarily engaged in the discovery, development, and commercialization of products and services aimed at improving human health through the detection and treatment of calcifying nanoparticles (CNPs). The company manufactures and markets in vitro diagnostic (IVD) kits, including assays, antibodies, and reagents, with key diagnostic assay products comprising NANO-CAPTURE and NANO-SERO. In addition to diagnostic products, Nanobac conducts research and clinical studies targeting urological diseases such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney disease, alongside cardiovascular diseases. Nanobac Pharmaceuticals operates primarily in the United States, with headquarters located in Tampa, Florida, and was founded in 1994. The company serves healthcare, biotechnology, and life sciences markets, focusing on advancing diagnostic tools and therapeutic solutions based on its proprietary technology related to calcifying nanoparticles. It was formerly known as HealthCentrics Inc. before changing its name in December 2002. Recent major developments include strategic partnerships and licensing agreements that enhance Nanobac’s pipeline and commercial reach. Notably, the company entered into license and collaboration agreements with MSD to co-develop multiple antibody-drug conjugate (ADC) assets for cancer treatment, including the exclusive license of sac-TMT outside Greater China while retaining rights within Greater China. Nanobac has also expanded its clinical trial activities in collaboration with partners like Ellipses Pharma and Windward Bio, advancing immuno-oncology assets with FDA fast-track designations and progressing through various phases of clinical development. These partnerships reflect the company's strategy to leverage global collaborations to accelerate innovation and commercialization in oncology and other therapeutic areas. The company’s ongoing focus on international collaborations and the refinement of its environmental, social, and governance (ESG) structure underline its commitment to sustainable growth and global market penetration. Nanobac Pharmaceuticals continues to pursue opportunities to bring innovative diagnostics and therapeutics to market, supported by a forward-looking portfolio that includes next-generation ADC drugs and other bio-lifescience products. Nanobac Pharmaceuticals, Incorporated remains engaged in the biotechnology and healthcare sectors with a specialized focus on targeting calcifying nanoparticles. Its core products include diagnostic kits and therapeutic candidates developed under strategic partnerships and license agreements, positioning the company within the translational medicine and personalized healthcare landscape. The company’s headquarters in Tampa, Florida, anchor its operations primarily in North America, while collaborations extend its reach internationally. This description incorporates the company’s main products and services along with its latest strategic partnerships and clinical advancements within the past one to two years.